Indications for: EVKEEZA
Adjunct to other LDL-C lowering therapies for the treatment of patients with homozygous familial hypercholesterolemia (HoFH).
Limitations of Use:
Safety and efficacy have not been established for other causes of hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). Effects on cardiovascular morbidity and mortality have not been determined.
Give by IV infusion over 60mins. ≥12yrs: 15mg/kg once monthly (every 4 weeks).
<12yrs: not established.
Discontinue if serious hypersensitivity reactions occur; monitor and treat appropriately. Assess LDL-C when clinically appropriate; effects may be measured as early as 2 weeks after initiation. Embryo-fetal toxicity. Advise females of reproductive potential to use effective contraception during and for at least 5 months after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers.
Angiopoietin-like 3 (ANGPTL3) inhibitor.
Nasopharyngitis, influenza-like illness, dizziness, rhinorrhea, nausea; hypersensitivity reactions.
Generic Drug Availability:
Single-dose vial (2.3mL, 8mL)—1